Review
Accepted on 20 Nov 2025
Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: Molecular Basis and New Targets
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Type at least 3 characters
2,029 articles
Original Research
Published on 20 Nov 2025
Pan-cancer analysis reveals ELFN1 as a novel prognostic biomarker and immunotherapeutic target associated with tumor microenvironment remodeling and promoting malignant phenotypes in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1583277
- 591 views
Case Report
Published on 20 Nov 2025
Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1686070
- 161 views
Case Report
Published on 19 Nov 2025
Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1667628
- 186 views
Review
Published on 19 Nov 2025
Advances in the study of FOXQ1: biological functions and mechanisms
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1650022
- 104 views
Case Report
Published on 19 Nov 2025
Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1636989
- 297 views
Review
Published on 19 Nov 2025
Targeting TEAD in cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1692512
- 244 views
Original Research
Published on 19 Nov 2025
Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1631415
- 435 views
Original Research
Published on 19 Nov 2025
CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1626301
- 314 views
Brief Research Report
Accepted on 18 Nov 2025
TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 124 views
Case Report
Accepted on 18 Nov 2025
TP53 Heterogeneous Alteration in Grade 3 Type Ⅰ Gastric NET: A Case Implicating Primary Tumor Progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Published on 18 Nov 2025
Prognostic alternative mRNA splicing in lung adenocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1579017
- 477 views
Systematic Review
Accepted on 17 Nov 2025
The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 103 views
Original Research
Accepted on 17 Nov 2025
Mechanistic Role of CD82 Palmitoylation in Augmenting Antitumor Drug Sensitivity via Apoptosis Regulation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Accepted on 17 Nov 2025
Targeting Endoplasmic reticulum Stress-Induced CLGN Resensitizes Hepatocellular Carcinoma to Apoptosis: Paeonol Synergistically Enhances Efficacy by Dual Inhibition of CLGN and NF-κB
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Systematic Review
Accepted on 17 Nov 2025
Efficacy and Safety of Anlotinib for the Treatment of Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology